Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

NCT06015542 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elranatamab

Sponsor

Thomas Lund

Collaborators

[object Object]
[object Object]